Though combination antiretroviral therapy (ART) can potently suppress HIV replication and reduce mortality, this suppression of HIV requires lifelong administration of at least three different medicines and does not eradicate HIV, which continues to cause inflammation, ongoing damage to multiple organs systems, and reduction in life expectancy. Moreover, the worldwide prevalence of HIV continues to increase and it does not seem feasible to administer ART to all people living with HIV. Therefore, it seems imperative that we continue to pursue strategies that could lead to viral eradication or functional cure. Two main barriers to eradicatio are the presence of latent infection, as originally described in the blood, and viral reservoirs in tissues such as the gut. Despite intensive study, most of which has been performed in model systems, it is unclear what mechanisms govern latent infection in the blood. Moreover, HIV replication occurs primarily in tissues such as the gut, where most HIV-infected cells probably reside. In addition, evidence suggests important differences between gut and blood in T cell phenotypes, distribution of infected cell types, activation status, HIV transcription levels, and response to activation, suggesting that different mechanisms may regulate HIV transcription (and hence latent infection) in the gut and blood. A crucial corollary is that the gut may respond differently to therapies designed to reactivate and clear latently- infected cells in the blood. Thus, there is a critical need to understand the mechanisms that govern latent vs. productive infection in the gut and how they differ from the blood. This application will investigate the mechanisms that control HIV transcription, and hence latent infection, in blood and different gut sites in samples from HIV-infected patients using a series of novel methods. Gut tissue and cells will be obtained by endoscopic biopsies from the ileum and rectum of HIV-infected patients and uninfected controls.
In aim 1, we will investigate the degree of transcriptional interference and progression through blocks to HIV transcriptional initiation and elongation in blood and gut cells from ART-treated patients using a novel panel of qRT-PCR assays specific for different HIV transcripts.
In aim 2, we will use novel gut cell culture and stimulation assays to measure the degree to which different latency reversal agents can induce cellular HIV transcription and virus production from cells from gut and blood.
In aim 3, we will use a novel single cell analysis assay to simultaneously quantify multiple HIV and cellular transcripts in individual gut CD4+T cells, enabling us to: 1) distinguish HIV-uninfected from infected cells as well as infected cells that do and do not transcribe HIV RNA; and 2) investigate how these populations differ in T cell phenotype and expression of human genes implicated in HIV latency and antiviral defenses. The knowledge thus gained may ultimately contribute to new and improved therapies aimed at eradication or lifelong coexistence with HIV.

Public Health Relevance

Though antiviral medicines have revolutionized the lives of those with HIV, these therapies are expensive, require lifelong administration and monitoring, cause side effects and toxicities, do not prevent ongoing damage from HIV (average loss of 11 years of life), and are difficult to provide to everybody with HIV. In order to devise better therapies for HIV, it is imperative to understand how and why HIV persists on antiviral drugs. This study seeks to investigate the mechanisms that allow HIV to persist in the gut and blood, and to evaluate therapies aimed at overcoming latent infection in the gut and blood, in the hopes that this will lead to new and improved treatments aimed at curing HIV

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Perrin, Peter J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northern California Institute Research & Education
San Francisco
United States
Zip Code
Moron-Lopez, Sara; Kim, Peggy; S√łGaard, Ole S et al. (2018) Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals. AIDS :
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Yukl, Steven A; Kaiser, Philipp; Kim, Peggy et al. (2018) HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med 10:
Henrich, Timothy J; Hatano, Hiroyu; Bacon, Oliver et al. (2017) HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med 14:e1002417
Khan, Shahzada; Telwatte, Sushama; Trapecar, Martin et al. (2017) Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure. AIDS Res Hum Retroviruses 33:S40-S58
Kaiser, Philipp; Joshi, Sunil K; Kim, Peggy et al. (2017) Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. J Virol Methods 242:1-8
Trapecar, Martin; Khan, Shahzada; Roan, Nadia R et al. (2017) An Optimized and Validated Method for Isolation and Characterization of Lymphocytes from HIV+ Human Gut Biopsies. AIDS Res Hum Retroviruses 33:S31-S39
Cockerham, Leslie R; Yukl, Steven A; Harvill, Kara et al. (2017) A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. Pathog Immun 2:310-334
Koelsch, Kersten K; Rasmussen, Thomas A; Hey-Nguyen, William J et al. (2017) Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. J Acquir Immune Defic Syndr 75:328-337
Lee, Sulggi A; Bacchetti, Peter; Chomont, Nicolas et al. (2016) Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS One 11:e0160192

Showing the most recent 10 out of 12 publications